Tags: FDA

A wave of policy moves and tech developments is reshaping multiple sectors. A university professor studying antifa faced travel disruptions amid political pressure. ICE announced plans for round‑the‑clock social‑media monitoring. Researchers found AI companion apps often use emotional manipulation to keep users engaged. Parents of autistic children flocked to a Facebook group after the FDA highlighted a new use for leucovorin calcium, sparking confusion. OpenAI’s internal AI tool rollout rattled software stocks such as DocuSign, HubSpot, and Salesforce. Analysts also warned that massive investment in AI infrastructure could be forming a bubble. Weiterlesen

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Weiterlesen